DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Alibaba - 1 Wedbush - 1 Levi Strauss — - 1 Levi Strauss - 1 Cantor Fitzgerald - 1 DraftKings - 1 Jefferies - 1 CNBC's Hakyung Kim - 1
Top related locs:
Chicago , Illinois Alibaba — Thursday's
Top related orgs:
Ant Group - 1 JPMorgan - 1 Therapeutics - 1 TG Therapeutics - 1 Food and Drug Administration - 1

Search resuls for: "TG Therapeutics"


6 mentions found


☆ Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
  + stars: | 2023-07-07 | by ( Brian Evans | ) www.cnbc.com   time to read: +2 min
Rivian Automotive — The electric vehicle maker popped more than 16% after Wedbush raised its price target on shares to $30 from $25, citing an improved outlook. Levi Strauss — Shares of the jeans maker slumped 6.7% after the company cut its full-year profit forecast on Thursday. Levi Strauss now expects an adjusted $1.10 to $1.20 per share compared to a previous range of $1.30 to $1.40. First Solar — The solar company climbed 4.6% after receiving a five-year revolving line of credit as well as a guarantee for a $1 billion facility. The firm said it sees sales of TG Therapeutics' treatment for relapsing forms of multiple sclerosis, Briumvi, to come in above expectations for the second quarter.
Persons: Alibaba, Wedbush, Levi Strauss —, Levi Strauss, Cantor Fitzgerald, DraftKings, Jefferies, CNBC's Hakyung Kim Organizations: Reuters, Ant Group, JPMorgan, Therapeutics, TG Therapeutics, Food and Drug Administration Locations: Chicago , Illinois, Alibaba —, Thursday's
☆ US FDA proposes more rigorous trials for accelerated nod of cancer therapy
  + stars: | 2023-03-24 | by ( ) www.reuters.com   time to read: +2 min
March 24 (Reuters) - The U.S. health regulator on Friday proposed cancer drug developers in most cases conduct more rigorous trials to seek accelerated approval for their candidates. Accelerated approvals allow quicker nod for therapies that target serious and life-threatening conditions. The FDA proposed using "randomized controlled trials" (RCT) where patients receive either a therapy or another alternate treatment, compared to conducting a trial testing the drug without a comparator, known as single-arm studies. "Given the limitations of single-arm trials, a randomized controlled trial is the preferred approach to support an application for accelerated approval," the FDA said. Drug developers usually depend on such "single-arm" studies to gain accelerated approval, and then conduct another trial post-nod to confirm clinical benefits.
☆ Cramer's lightning round: Parker-Hannifin is a buy
  + stars: | 2023-02-07 | by ( Krystal Hur | ) www.cnbc.com   time to read: +1 min
I would buy it here." Waste Management Inc : "Everyone thought that quarter was not that great and was telling me to buy Republic Services . Loading chart...Illumina Inc : "If you're going to be in that business, there's only two. Loading chart...TG Therapeutics Inc : "This is [run by CEO] Mike Weiss. I think that you've got a winner, and I need to hear it from you."
☆ Stocks making the biggest moves midday: TG Therapeutics, Micron Technology, ChargePoint and more
  + stars: | 2022-12-30 | by ( Tanaya Macheel | ) www.cnbc.com   time to read: +1 min
A ChargePoint station at the New Carrollton Branch Library in New Carrollton, Md. TG Therapeutics — Shares jumped more than 9% after the biotech company announced this week that the U.S. Food and Drug Administration approved its treatment for relapsing forms of multiple sclerosis in adults. Micron Technology — Shares of the chipmaker dropped 2% after the stock got downgraded to hold from buy by Argus Research. ChargePoint — The maker of EV charging technology saw shares rise more than 4% after Q-GRG VII (CP) Investment Partners bought more than 1.4 million shares, according to a filing with the U.S. Securities and Exchange Commission. The move came as the company announced plans to raise cash by selling up to $125 million of senior convertible bonds.
☆ Stocks making the biggest moves midday: Netflix, Cal-Maine Foods, Southwest and more
  + stars: | 2022-12-29 | by ( Samantha Subin | ) www.cnbc.com   time to read: +2 min
Cal-Maine Foods — Cal-Maine shares shed 15% after reporting earnings that fell short of Wall Street's expectations even as the egg producer reported record sales. Southwest Airlines — The airline stock rose more than 3%, paring back losses from the previous session when it dropped more than 5%. Severe disruptions at Southwest Airlines have drawn outsized criticism from frustrated travelers, who have dealt with thousands of canceled flights from airlines this week because of winter weather. Southwest Airlines canceled another 60% of its flights on Wednesday. Apple — The iPhone maker's stock rose more than 3% after hitting its lowest level since June 2021 earlier in the week.
☆ U.S. FDA approves TG Therapeutics' multiple sclerosis drug
  + stars: | 2022-12-28 | by ( Sriparna Roy Khushi Mandowara | Sriparna Roy | Khushi Mandowara | ) www.reuters.com   time to read: +1 min
Dec 28 (Reuters) - TG Therapeutics Inc (TGTX.O) said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up nearly 9% in afternoon trade. TG Therapeutics said it was expecting to launch the drug, branded as Briumvi, in the first quarter of 2023, but did not give details on its pricing. Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. Unlike other MS drugs that target T cells, Briumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to neurological disease.
0 next >>
Total: 6